Smartest Doc
Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist)-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre
Irish Journal of Medical Science, 03/30/2012
Clinical Article
Chan VO et al. – The sensitivity and PPV of Primovist–enhanced MRI (P–MRI) was superior to that of MDCT and PET/CT. P–MRI probably has the most added value if used after MDCT and PET/CT in patients still considered eligible for liver resection.
Methods- This was a retrospective study of consecutive referrals for CRC liver metastases.
- All patients had MDCT, PET/CT and P-MRI examinations within 3 months of each other.
- They were divided into 2 groups: resected and unresected.
- Patients in the resected group underwent liver resection within 3 months of the imaging studies.
- In the unresected group, patients were unresectable by imaging criteria or are awaiting surgery.
- Standard of reference (SOR) was intra-operative ultrasound findings and pathology for the resected group.
- Intermodality comparison was the SOR for the unresected group.
- Number of lesions identified by each imaging modality for each patient was recorded. Sensitivity (95% CI) and PPV were calculated for each imaging modality in the resected group.
- There were 19 patients in the resected group and 11 patients in the unresected group.
- The sensitivity (96%) and PPV (0.91) of P-MRI were both superior to that of MDCT (P = 0.0009) and PET/CT (P = 0.0003).
- Intermodality comparison showed that P-MRI detected more lesions than MDCT and PET/CT.